中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2014年
35期
43-44
,共2页
王利强%郜风丽%刘淑娟%杨芬%周会杰%陈派强%郄永强%姚文森
王利彊%郜風麗%劉淑娟%楊芬%週會傑%陳派彊%郄永彊%姚文森
왕리강%고풍려%류숙연%양분%주회걸%진파강%극영강%요문삼
钠/碘同向转运体抗体%自身免疫性甲状腺疾病%甲状腺球蛋白%甲状腺球蛋白抗体%甲状腺过氧化物酶抗体
鈉/碘同嚮轉運體抗體%自身免疫性甲狀腺疾病%甲狀腺毬蛋白%甲狀腺毬蛋白抗體%甲狀腺過氧化物酶抗體
납/전동향전운체항체%자신면역성갑상선질병%갑상선구단백%갑상선구단백항체%갑상선과양화물매항체
Sodium/iodide symporter antibody%Autoimmune thyroid disease%Thyroglobulin%Thyroglobulin antibody%Thyroid peroxidase antibody%Correlation
目的：研究不同自身免疫性甲状腺疾病（AITD)钠/碘同向转运体抗体（NISAb)与甲状腺球蛋白抗体（TgAb),甲状腺过氧化物酶抗体（TPOAb)含量之间的相关性，并观察甲亢患者药物治疗前后NISAb含量的变化。方法选择甲亢（GD)患者，桥本甲状腺功能低下者（HT),健康正常人组（NC)各40例，检测NISAb、TgAb、TPOAb含量，比较NISAb含量与TgAb、TPOAb含量之间的相关性，并分析20例甲亢患者药物治疗前后NISAb含量的差异。结果（1)甲亢患者NISAb与TgAb、TPOAb含量,相关系数R分别为0.90、0.85， P均<0.05,呈直线相关性，GD患者 NISAb与TgAb，TPOAb呈正相关，HT患者NISAb与TgAb、TPOAb含量,相关系数r分别为-0.64、-0.52，P均<0.05,呈线性负相关性。正常人群NISAb, TgAb，TPOAb含量之间,相关性分析，P值分别为0.63、0.22，P均>0.05,无线性相关性。（2)甲亢患者NISAb含量与正常人群对比分析，t检验， P<0.05, NISAb含量高于正常人群。HT患者NISAb含量与正常人群对比分析，t检验， P<0.05，NISAb含量低于正常人群。（3)甲亢患者治疗前后NISAb含量对比分析，t检验，P<0.05差异有统计学意义。结论（1)GD和HT患者血浆NISAb含量与TgAb, TPOAb 含量之间具有相关性,GD患者血浆NISAb含量与TgAb,TPOAb含量之间呈正相关，HT患者血浆NISAb含量与TgAb,TPOAb含量之间呈负相关。（2) GD患者血浆NISAb含量高于健康人群，HT患者NISAb含量低于健康人群。（3) GD患者治疗后NISAb含量明显降低，差异明显。
目的：研究不同自身免疫性甲狀腺疾病（AITD)鈉/碘同嚮轉運體抗體（NISAb)與甲狀腺毬蛋白抗體（TgAb),甲狀腺過氧化物酶抗體（TPOAb)含量之間的相關性，併觀察甲亢患者藥物治療前後NISAb含量的變化。方法選擇甲亢（GD)患者，橋本甲狀腺功能低下者（HT),健康正常人組（NC)各40例，檢測NISAb、TgAb、TPOAb含量，比較NISAb含量與TgAb、TPOAb含量之間的相關性，併分析20例甲亢患者藥物治療前後NISAb含量的差異。結果（1)甲亢患者NISAb與TgAb、TPOAb含量,相關繫數R分彆為0.90、0.85， P均<0.05,呈直線相關性，GD患者 NISAb與TgAb，TPOAb呈正相關，HT患者NISAb與TgAb、TPOAb含量,相關繫數r分彆為-0.64、-0.52，P均<0.05,呈線性負相關性。正常人群NISAb, TgAb，TPOAb含量之間,相關性分析，P值分彆為0.63、0.22，P均>0.05,無線性相關性。（2)甲亢患者NISAb含量與正常人群對比分析，t檢驗， P<0.05, NISAb含量高于正常人群。HT患者NISAb含量與正常人群對比分析，t檢驗， P<0.05，NISAb含量低于正常人群。（3)甲亢患者治療前後NISAb含量對比分析，t檢驗，P<0.05差異有統計學意義。結論（1)GD和HT患者血漿NISAb含量與TgAb, TPOAb 含量之間具有相關性,GD患者血漿NISAb含量與TgAb,TPOAb含量之間呈正相關，HT患者血漿NISAb含量與TgAb,TPOAb含量之間呈負相關。（2) GD患者血漿NISAb含量高于健康人群，HT患者NISAb含量低于健康人群。（3) GD患者治療後NISAb含量明顯降低，差異明顯。
목적：연구불동자신면역성갑상선질병（AITD)납/전동향전운체항체（NISAb)여갑상선구단백항체（TgAb),갑상선과양화물매항체（TPOAb)함량지간적상관성，병관찰갑항환자약물치료전후NISAb함량적변화。방법선택갑항（GD)환자，교본갑상선공능저하자（HT),건강정상인조（NC)각40례，검측NISAb、TgAb、TPOAb함량，비교NISAb함량여TgAb、TPOAb함량지간적상관성，병분석20례갑항환자약물치료전후NISAb함량적차이。결과（1)갑항환자NISAb여TgAb、TPOAb함량,상관계수R분별위0.90、0.85， P균<0.05,정직선상관성，GD환자 NISAb여TgAb，TPOAb정정상관，HT환자NISAb여TgAb、TPOAb함량,상관계수r분별위-0.64、-0.52，P균<0.05,정선성부상관성。정상인군NISAb, TgAb，TPOAb함량지간,상관성분석，P치분별위0.63、0.22，P균>0.05,무선성상관성。（2)갑항환자NISAb함량여정상인군대비분석，t검험， P<0.05, NISAb함량고우정상인군。HT환자NISAb함량여정상인군대비분석，t검험， P<0.05，NISAb함량저우정상인군。（3)갑항환자치료전후NISAb함량대비분석，t검험，P<0.05차이유통계학의의。결론（1)GD화HT환자혈장NISAb함량여TgAb, TPOAb 함량지간구유상관성,GD환자혈장NISAb함량여TgAb,TPOAb함량지간정정상관，HT환자혈장NISAb함량여TgAb,TPOAb함량지간정부상관。（2) GD환자혈장NISAb함량고우건강인군，HT환자NISAb함량저우건강인군。（3) GD환자치료후NISAb함량명현강저，차이명현。
Objective To investigate the correlation of sodium/iodide symporter antibody (NISAb) with the content of TgAb and TPOAb among different autoimmune thyroid disease (AITD), and observe the changes of NISAb of the patients with hyperthyroidism before and after drug treatment. Methods 40 patients with Gravesˊ disease (GD), 40 with hashimoto low thyroid function (HT) and 40 healthy normal controls (NC) were selected. Venous blood of the patients was collected. The content of NISAb was detected by ELISA method, while the content of TgAb and TPOAb were detected by electrochemical luminescence method. And the correlation of the content of NISAb with that of TgAb and TPOAb was compared. The content of NISAb in 20 cases with GD before and after the medication was analyzed. Results (1) The correlation coefficient R between NISAb and TgAb, TPOAb content was respectively 0.90 and 0.85 in patients with hyperthyroidism (both P<0.05). NISAb and TgAb, TPOAb was positively linear correlated in patients with GD. The correlation coefficient R between NISAb and TgAb, TPOAb content was respectively -0.64 and -0.52 in patients with hashimoto low thyroid function (both P<0.05). NISAb and TgAb, TPOAb was negatively linear correlated in patients with hashimoto low thyroid function. The P value between NISAb, TgAb and TPOAb content was respectively 0.63 and 0.22 (both P>0.05) in the normal controls by correlation analysis. There was no linear correlation between them. (2) The content of NISAb in patients with GD was higher than that in the normal healthy population by t test (P<0.05). The content of NISAb in patients with HT was lower than that in the normal healthy population by t test (P<0.05). (3) There were statistically significant differences of NISAb content before and after treatment in patients with hyperthyroidism by t test (P<0.05). Conclusion (1) The content of plasma NISAb and TgAb, TPOAb content are relevant between patients with GD and HT patients. The content of plasma NISAb is positively correlated with that of TgAb and TPOAb in patients with GD, while the content of plasma NISAb is negatively correlated with that of TgAb and TPOAb in patients with HT. (2) The content of plasma NISAb in patients with GD is higher than that in the normal healthy population, and the content of NISAb in HT patients is lower than that in the healthy population. (3) The content of NISAb has obviously decreased in patients with GD after treatment, and the difference is obvious.
